MedTrace Logo

GOREISAN for Heart Failure (GOREISAN-HF) Trial

NCT04691700 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1179

Last updated 2026-01-06

No results posted yet for this study

Summary

The objective of the GOREISAN-HF trial is to assess the effect of the administration of Goreisan (TJ-17) plus standard therapy compared to standard therapy alone on the improvement rate of cardiac edema and clinical outcomes in worsening congestive heart failure with volume overload.

Conditions

Interventions

DRUG

Goreisan

Add Goreisan 7.5g per day to standard treatment with the intention to reduce or discontinue the existing diuretics

DRUG

Standard Treatment

Standard therapy without Goreisan

Sponsors & Collaborators

  • Takeshi Morimoto

    lead OTHER

Principal Investigators

  • Takeshi Kimura, MD, PhD · Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-19
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04691700 on ClinicalTrials.gov